Experiences with
Chronic leukaemia5,610 public posts
ERIC recommendations for TP53 mutation analysis in CLL - 2024 update
Following on from the interesting discussion on testing for 17p del and TP53 disruption/mutations I thought it might be worth posting this paper which sets out how this testing and analysis is done. It's published by ERIC, the European Research Initiative on CLL, and is the 2024 update of the last
Want to take advantage of all our features? Just log in!
or
UK Telegraph Newspaper report
Mike Peters from a Welsh music band The Alarm had CLL for 29 years but was diagnosed with a Richters transformation this year.
He received treatment in the UK STELLAR trial which adds Acalabrutinib to the usual R-CHOP chemotherapy. He's had a spectacular response and his story is here
http://digitaleditions.telegraph.co.uk
"Accelerated" chronic lymphocytic leukemia/small lymphocytic lymphoma: unraveling CLL/SLL biological gray zone in the era of novel therapies
Encouraging news in this abstract from CLL/SLL researchers at the Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, for those with aggressive/complex karyotype CLL/SLL*
https://pubmed.ncbi.nlm.nih.gov/39243299
The abstract, with my emphasis;
[i]Accelerated
Measurable residual disease (MRD) status predicts Progression Free Survival (PFS) for patients with Chronic Lymphocytic Leukemia (CLL)
[i]Measurable residual disease (MRD) refers to the presence of disease at low levels not detected by conventional pathologic analysis. The association of MRD status as a surrogate end point of clinical outcome in chronic lymphocytic leukemia (CLL) has not been established in the era of targeted agents